Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
暂无分享,去创建一个
Damon L. Meyer | Michael M C Sun | C. Cerveny | K. J. Hamblett | P. Senter | D. Chace | J. Lenox | K. Kissler | Starr X Bernhardt | Anastasia K Kopcha | R. Zabinski | D. Meyer | J. A. Francisco | Kevin J. Hamblett
[1] S. Shah,et al. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. , 1995, Cancer research.
[2] S. Shah,et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. , 1992, Cancer research.
[3] K. Shitara,et al. The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.
[4] V. Diehl,et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cells , 1982, Nature.
[5] Damon L. Meyer,et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy , 2003, Nature Biotechnology.
[6] B. Nardelli,et al. Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys , 2002, Journal of Pharmacology and Experimental Therapeutics.
[7] Irwin Hollander,et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. , 2002, Bioconjugate chemistry.
[8] P. Trail,et al. Synthesis and antitumor activity of the immunoconjugate BR96-Dox , 1996 .
[9] A. Wahl,et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. , 2002, Cancer research.
[10] B. Cheson. Radioimmunotherapy of non-Hodgkin lymphomas. , 2003, Blood.
[11] P. Trail,et al. (6-Maleimidocaproyl)hydrazone of doxorubicin--a new derivative for the preparation of immunoconjugates of doxorubicin. , 1993, Bioconjugate chemistry.
[12] D. Baccanari,et al. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] Damon L. Meyer,et al. Chapter 23. Recent advances in antibody drug conjugates for cancer therapy , 2003 .
[14] Toshiki Watanabe,et al. CD30: expression and function in health and disease. , 1998, Seminars in immunology.
[15] X. H. Chen,et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] J. Lundblad,et al. A New Preparation of Modified Immune Serum Globulin (Human) Suitable for Intravenous Administration , 1981, Vox sanguinis.
[17] A. Tolcher,et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] L. Presta,et al. Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.
[19] I. Bernstein,et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. , 2002, Bioconjugate chemistry.
[20] M. Juweid. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] I. Bernstein,et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. Carter,et al. Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.
[23] Ira Pastan,et al. Immunotoxins in cancer therapy. , 1999, Current opinion in investigational drugs.
[24] P. Trail,et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. , 2002, Bioconjugate chemistry.
[25] K. Lennert,et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. , 1985, Blood.
[26] H. Stein,et al. High proliferative activity of Reed Sternberg associated antigen Ki-1 positive cells in normal lymphoid tissue. , 1986, Journal of clinical pathology.
[27] M. Berger,et al. A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma , 2003, Cancer Immunology, Immunotherapy.
[28] J. Murray,et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Damon L. Meyer,et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. , 2003, Blood.
[30] P. Trail,et al. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates. , 1999, Bioconjugate chemistry.